Mode
Text Size
Log in / Sign up
Phase 3 N=72 Randomized Triple-blind Treatment

Metoprolol to Reduce Perioperative Myocardial Injury

Heart Diseases

Enrolled (actual)
72
Serious AEs
0.0%
Results posted
Feb 2025
Primary outcome: Primary: Effectiveness of Beta-blocker Therapy Reducing Post-operative Myocardial Injury — 9; 11 participants

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Metoprolol Tartrate (Drug); Placebo (Drug)
Age
Adult, Older Adult · 50+ yrs
Sex
All
Sponsor
University of Chicago
Primary completion
Apr 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Effectiveness of Beta-blocker Therapy Reducing Post-operative Myocardial Injury
9; 11
SECONDARY
Effectiveness in Reduction of Major Adverse Cardiac Events (MACE)
0; 0
SECONDARY
Monitor Post-operative Myocardial Ischemia
0; 0
SECONDARY
Number of Stroke Related Events Following Surgery
0; 0
SECONDARY
Number of Participants Having Vasopressor Therapy to Regulate Symptomatic Hypotension
0; 0
SECONDARY
Number of Participant Incidence of Clinically Relevant Bradycardia
0; 1
SECONDARY
Participants Number of Days Spent Post-operative Hospitalization
2.5; 2.5; 2; 3
SECONDARY
Patient Recovery Progress Events at 30-days Post-operative.
0; 0
SECONDARY
Participant Post-operative Mortality at 1-year Following Surgery
0; 0

Summary

The purpose of this research study is to test if a commonly used, FDA-approved medication, called metoprolol, given at the conclusion of anesthesia following surgery, and during postoperative admission, reduces the possibility of heart related complications in patients with coronary artery disease (CAD).

Eligibility Criteria

Inclusion Criteria

  • Age >= 50 years
  • Beta-blocker naïve [30 days prior to surgery]
  • Previously diagnosed coronary artery disease (CAD), or
  • History of peripheral vascular disease (PVD), or
  • Chronic kidney disease (CKD) [eGFR ≤60ml/min], or
  • History of positive stress test or
  • At high risk for CAD (must meet at least 2 criteria):

i. Age >= 70 years ii. Hypertension iii. Diabetes requiring oral medication or insulin iv. Current smoker or some days smoker within the past 2 years

  • Major non-cardiac, elective surgery under general anesthesia

Exclusion Criteria

Subjects will not be enrolled if any of the following criteria exist:

  • History of stroke, or transient ischemic attack (TIA)
  • Previously diagnosed carotid disease, i.e., either 70% unilateral or 50% bilateral carotid occlusion.
  • Heart rate <=55bpm
  • Congestive heart failure with New York Heart Association(NYHA) Functional Classification of III-IV or left ventricular heart failure with ejection fraction ≤50%
  • Severe valvular regurgitation
  • Second or third degree atrioventricular (AV) block without pacemaker
  • Active asthma or chronic obstructive pulmonary disease (COPD) with symptoms or resolving symptoms on day of surgery
  • Anemia [HB<=9g/dL]
  • Allergy to beta-blockade drugs
  • Unwilling or unable to give consent for participation
  • Undergoing any carotid endarterectomy, endovascular, endoscopic, superficial, or ambulatory procedures
  • Pregnancy or lactating women
  • Prisoners
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03138603). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search